德谷门冬双胰岛素联合二甲双胍治疗2型糖尿病的效果及对氧化-抗氧化平衡的影响

Effect of Insulin Degludec and Insulin Aspart Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus and Its Effect on the Oxidation-antioxidant Balance

目的:探讨德谷门冬双胰岛素联合二甲双胍治疗2型糖尿病的效果及对氧化-抗氧化平衡的影响。方法:选取2019年8月-2022年1月佳木斯市中心医院收治的90例2型糖尿病患者,使用随机数字表法将其分为联合用药组(n=45)及单一用药组(n=45)。单一用药组患者接受二甲双胍治疗,联合用药组患者接受德谷门冬双胰岛素联合二甲双胍治疗。对比两组的血糖指标、胰岛功能指标、氧化产物、抗氧化指标及不良反应发生率。结果:治疗前,两组空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)比较,差异均无统计学意义(P>0.05);治疗后,两组FPG、2 h PG及HbA1c均降低,联合用药组均低于单一用药组,差异均有统计学意义(P<0.05)。治疗前,两组胰岛β细胞功能指数(HOMA-β)、空腹胰岛素(FINS)及稳态模型胰岛素抵抗指数(HOMA-IR)比较,差异均无统计学意义(P>0.05);治疗后,两组HOMA-β均升高,联合用药组高于单一用药组;两组FINS及HOMA-IR均降低,联合用药组均低于单一用药组,差异均有统计学意义(P<0.05)。治疗前,两组丙二醛(MDA)、晚期氧化蛋白产物(AOPP)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、总抗氧化能力(T-AOC)比较,差异均无统计学意义(P>0.05);治疗后,两组SOD、CAT及T-AOC均升高,联合用药组均高于单一用药组;两组MDA及AOPP均降低,联合用药组均低于单一用药组,差异均有统计学意义(P<0.05)。联合用药组的不良反应发生率(4.44%)低于单一用药组(17.78%),差异有统计学意义(P<0.05)。结论:德谷门冬双胰岛素联合二甲双胍治疗2型糖尿病可显著降低血糖水平,强化胰岛功能,改善氧化-抗氧化平衡,减少不良反应的发生,安全有效。

Objective:To investigate the effect of Insulin Degludec and Insulin Aspart combined with Metformin in the treatment of type 2 diabetes mellitus and its effect on oxidation-antioxidation balance.Method:Ninety patients with type 2 diabetes mellitus admitted to the Jiamusi Central Hospital from August 2019 to January 2022 were selected and divided into the combined drug group(n=45)and the single drug group(n=45)by the random number table method.Patients in the single drug group was treated with Metformin and patients in the combined drug group were treated with Insulin Degludec and Insulin Aspart combined with Metformin.Blood glucose indexes,pancreatic function indexes,oxidation products,antioxidant indexes and the incidence of adverse reactions were compared between the two groups.Result:Before treatment,the differences in fasting plasma glucose(FPG),2 h postprandial plasma glucose(2 h PG)and glycosylated hemoglobin(HbA1c)between the two groups were not statistically significant(P>0.05);after treatment,FPG,2 h PG and HbA1c were decreased in both groups,and the combined drug group were lower than those of the single drug group,with statistical significances(P<0.05).Before treatment,there were no significant differences in homeostasis model assessment-β(HOMA-β),fasting insulin(FINS)and homeostasis model assessment-insulin resistance(HOMA-IR)index between the two groups(P>0.05);after treatment,HOMA-βincreased in both groups,and the combined drug group was higher than that of the single drug group;FINS and HOMA-IR decreased,and the combined drug group were lower than those the single drug group,the differences were statistically significant(P<0.05).Before treatment,the levels of malondialdehyde(MDA),advanced oxidation protein product(AOPP),superoxide dismutase(SOD),catalase(CAT),and total antioxidant capacity(T-AOC)in the two groups were not statistically significant(P>0.05);after treatment,the SOD,CAT,and T-AOC in the two groups were increased,the combined drug group were higher than those of the single drug group;the MDA and AOPP were lower in the combined drug group than those in the single drug group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the combined drug group(4.44%)was lower than that in the single drug group(17.78%),the difference was statistically significant(P<0.05).Conclusion:Insulin Degludec and Insulin Aspart combined with Metformin in the treatment of type 2 diabetes mellitus can significantly reduce blood glucose level,strengthen pancreatic islet function,improve oxidation-antioxidation balance,reduce the occurrence of adverse reactions,and is safe and effective.